Regulatory Viridian wins FDA approval for Lumvoa for thyroid eye disease PharmaTimesCompany secures first commercial product with data for active and chronic TEDOphthalmologyRead full story pharminent June 29, 2026 (Last updated: June 30, 2026) PharmaTimes Company secures first commercial product with data for active and chronic TED Ophthalmology Read full story Post navigation Previous: Ipsen charts $1.75bn course for Kartos acquisitionNext: Biogen trims Apellis pipeline and R&D team after $5.6bn takeover Related Stories Regulatory UK regulators greenlight Lilly’s Foundayo, intensifying Novo competition pharminent August 11, 2026 Regulatory Replimune rebounds to win FDA approval of melanoma drug pharminent August 6, 2026 Regulatory Takeda’s first-in-class narcolepsy drug claims FDA approval pharminent August 6, 2026
